Zobrazeno 1 - 10
of 6 228
pro vyhledávání: ''
Autor:
Amaury Druet, Caroline Viala, Yann Touchefeu, Jean-François Mosnier, Tamara Matysiak-Budnik, Erwan Corbineau
Publikováno v:
Clinical Colorectal Cancer. 21:e98-e101
Clinical Practice Points • Sinusoidal obstruction syndrome (SOS) is a life-threatening complication of oxaliplatin-based chemotherapy. • Nodular regenerative hyperplasia can be associated at a late stage of SOS, and should be suspected in case of
Autor:
Tadashi Yoshino, Naoya Nakamura, Misa Sakamoto, Tomoka Ikeda, Yuria Egusa, Yoshito Nishimura, Yasuharu Sato, Azusa Fujita, Misato Doi, Noriko Iwaki, Asami Nishikori, Midori Filiz Nishimura, Yuka Gion
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 417-432 (2022)
Cancer Medicine
Cancer Medicine
Background Most patients with methotrexate‐associated lymphoproliferative disorder (MTX‐LPD) show diffuse large B‐cell lymphoma (DLBCL) or classic Hodgkin lymphoma (CHL) types. Patients with MTX‐LPD often have spontaneous remission after MTX
Publikováno v:
Internal Medicine. 61:87-90
A 56-year-old woman with rheumatoid arthritis who had been taking methotrexate (MTX) for six years visited our hospital with dyspnea and dizziness. Abdominal ultrasonography revealed mild splenomegaly. Laboratory examinations showed a marked elevatio
Autor:
Ainsley Barry, Tina Mills-Baldock, Sam Khan, Timothy Iveson, Athanasios Pouptsis, Chloe Holden, Anne Thomas, Bryony Eccles, Liyana Satterthwaite, Vasileios Angelis, Christina Karampera, Paul Ross, Sherif Abdel-Raouf, Alicja Synowiec, Kai-Keen Shiu, Maria Martinou, M Hill, Meera Chauhan, Mark Baxter, Chara Stavraka, Janet Graham, Sally Young
Publikováno v:
Clinical Colorectal Cancer. 20:342-349
BACKGROUND The orally administered combination trifluridine/tipiracil has been approved as third line treatment in mCRC, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study. PATIENT AND METHODS We performed
Autor:
Thomas Walter, Denis Smith, Bernard Goichot, Vincent Hautefeuille, Louis de Mestier, Groupe d’Etude des Tumeurs Endocrines, Guillaume Cadiot, Christine Do Cao, Côme Lepage, Mathias Brugel, Vinciane Rebours
Publikováno v:
Pancreatology. 21:1531-1539
Background Vasoactive intestinal peptide-secreting tumor (VIPoma) is a very rare, life-threatening, functioning pancreatic neuroendocrine tumor (pNET). The efficacy of antitumor therapies against functioning symptoms and tumor burden have been poorly
Autor:
Yoshiaki Murakami, Shingo Seo, Hiroyuki Otsuka, Yasushi Hashimoto, Naru Kondo, Shinya Takahashi, Takeshi Sudo, Kenjiro Okada, Tatsuaki Sumiyoshi, Kenichiro Uemura
Publikováno v:
European Journal of Cancer. 159:215-223
Background The prognosis of patients with borderline resectable pancreatic cancer with arterial contact (BRPC-A) is extremely poor, and effective preoperative treatment is indispensable. We evaluated the clinical efficacy and safety of neoadjuvant ch
Autor:
Bei Zhang, Wenzhuo He, Dongsheng Zhang, Xiuxing Chen, Fenghua Wang, Yixing Wang, Qi Quan, Guifang Guo
Publikováno v:
Current Oncology, Vol 28, Iss 23, Pp 209-219 (2021)
Current Oncology
Volume 28
Issue 1
Pages 23-219
Current Oncology
Volume 28
Issue 1
Pages 23-219
Background: There have not been any head-to-head prospective studies to compare the effects of different chemotherapy regimens as first-line treatments for unresectable pancreatic cancer (UPC). We aimed to compare the effectiveness of nab-paclitaxel
Autor:
Huabin Hu, Weiwei Li, Xiaoyu Xie, Jianxia Li, Miaomiao Ding, Jianwei Zhang, Zehua Wu, Jiayu Ling, Yue Cai, Yanhong Deng
Publikováno v:
Clinical Colorectal Cancer. 20:e240-e248
To evaluate the predictive implications and prognosis of mucinous adenocarcinoma (MAC) in locally advanced rectal cancer (LARC) with intensified neoadjuvant treatment.Individual patient data of LARC patients from 3 prospective clinical trials was ana
Publikováno v:
Clinical Colorectal Cancer. 20:e215-e225
Background Suboptimal completion of chemotherapy, which may involve reduced patient adherence, remains a serious issue and leads to reduced treatment efficacy. This study assessed the completion rates, risk factors for noncompletion, and cost impact
Autor:
Yang Zhu, Shu Tian, Hua Zhong, Wenhao Zhang, Lifeng Wang, Rong Tao, Zhi-Chao Li, Hao Ding, Lina Jin, Chuanying Zhu, Yu-Jie Ma, Chuan-xu Liu, Siguo Hao, Lan Xu
Publikováno v:
British Journal of Haematology. 196:939-946
Early-stage natural killer/T-cell lymphoma (NK/TCL) patients usually receive a combination of chemotherapy and radiotherapy, but the optimal treatment approach has not yet been established. This study aimed to investigate the efficacy and safety prof